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Background: Transrectal prostate biopsy has limited diagnostic accuracy. Prostate Imaging Compared to Transperineal
Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE) was a paired-cohort confirmatory study
designed to assess diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) in men requiring a repeat
biopsy.
Methods: All underwent 3 T mpMRI and transperineal template prostate mapping biopsies (TTPM biopsies). Multiparametric MRI
was reported using Likert scores and radiologists were blinded to initial biopsies. Men were blinded to mpMRI results. Clinically
significant prostate cancer was defined as Gleason X4þ 3 and/or cancer core length X6mm.
Results: Two hundred and forty-nine had both tests with mean (s.d.) age was 62 (7) years, median (IQR) PSA 6.8 ngml (4.98–9.50),
median (IQR) number of previous biopsies 1 (1–2) and mean (s.d.) gland size 37ml (15.5). On TTPM biopsies, 103 (41%) had
clinically significant prostate cancer. Two hundred and fourteen (86%) had a positive prostate mpMRI using Likert score X3;
sensitivity was 97.1% (95% confidence interval (CI): 92–99), specificity 21.9% (15.5–29.5), negative predictive value (NPV) 91.4%
(76.9–98.1) and positive predictive value (PPV) 46.7% (35.2–47.8). One hundred and twenty-nine (51.8%) had a positive mpMRI using
Likert score X4; sensitivity was 80.6% (71.6–87.7), specificity 68.5% (60.3–75.9), NPV 83.3% (75.4–89.5) and PPV 64.3% (55.4–72.6).
Conclusions: In men advised to have a repeat prostate biopsy, prostate mpMRI could be used to safely avoid a repeat biopsy with
high sensitivity for clinically significant cancers. However, such a strategy can miss some significant cancers and overdiagnose
insignificant cancers depending on the mpMRI score threshold used to define which men should be biopsied.
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The prostate cancer diagnostic pathway is very different to that of
almost all other solid organ cancers, in that it is calibrated to detect
subclinical disease but often misses clinically important disease
(Shaw et al, 2014). The imprecision comes from the transrectal
ultrasound-guided biopsy (TRUS biopsy) – a semirandom
deployment of needles into the prostate – that is the standard
recommendation to a man with an elevated PSA. Men in whom
diagnostic uncertainty remains unresolved often require repeat
biopsy (Abrahams et al, 2015).
Multiparametric magnetic resonance imaging (mpMRI) incor-
porates a number of imaging sequences that assess anatomy and
tissue characteristics such as cellular density and vascularity
(Valerio et al, 2014; Siddiqui et al, 2015; Turkbey et al, 2016). It
could be used as a triage diagnostic test by identifying those men
who might avoid a repeat prostate biopsy (Bossuyt et al, 2006). The
Prostate Imaging Compared to Transperineal Ultrasound-guided
biopsy for significant prostate cancer Risk Evaluation (PICTURE)
trial (Simmons et al, 2014) was designed to overcome methodo-
logical limitations related to the use of either TRUS biopsy or
radical prostatectomy as reference standards, with the former being
inaccurate and the latter incorporating selection biases as men had
to both test positive for cancer on a TRUS biopsy and then choose
to undergo surgery. It is likely that these inherently different
populations (contingent on the method of histological verification)
harbour different burdens of disease.
The PICTURE trial was a paired-cohort validating confirmatory
study designed to provide level 1b evidence on the diagnostic
accuracy of mpMRI in men who required further biopsies (Phillips
et al, 2009; Valerio et al, 2015). In other words, our study
comprised men who had tested either negative on a first TRUS
biopsy and had some indication for a repeat evaluation or tested
positive and required some form of reclassification. Our reference
standard was transperineal template prostate mapping biopsies
(TTPM biopsies), which are both accurate and avoid many of the
described biases. Transperineal template prostate mapping biopsies
can be applied to almost all men under evaluation and overcome
the random error of TRUS biopsy by sampling the whole prostate
every 5mm (Crawford et al, 2013).
MATERIALS AND METHODS
The PICTURE trial was a single-centre, ethics committee-
approved, registered validating confirmatory study reported to
STARD (Bossuyt et al, 2003). The full details of our protocol have
been published (Simmons et al, 2014). Ethics committee approval
for the study was granted by London City Road and Hampstead
National Research Ethics Committee (reference 11/LO/1657) and
the trial was registered on 6 December 2011. The study opened to
recruitment on 11 January 2012 and completed recruitment on 29
January 2014.
Eligibility. Men were eligible for the study if they had undergone
prior TRUS biopsy and were advised to undergo further biopsies as
part of standard care.
Index test. All eligible men underwent the index test (mpMRI)
using a 3 T magnetic field strength scanner with a pelvic-phased
array coil. Magnetic resonance imaging sequences included T1-
weighted, T2-weighted, diffusion weighting with high b-value
(b¼ 2000) sequence and apparent diffusion coefficient map using
multiple b-values (b¼ 0, 150, 500, 1000) and dynamic contrast
enhancement with gadolinium (Magnevist). Complete sequence
details can be found in our protocol publication (Simmons et al,
2014). Multiparametric MRIs were reported by an expert urologic
radiologist with over 5 years of experience in interpreting prostate
MRIs. The radiologist was blinded to previous TRUS-biopsy
results, but given the PSA level and any other risk factors.
Reporting was carried out using a 5-point Likert scale for the
likelihood of the presence of clinically significant disease: ‘1’ and ‘2’
were designated for prostates ‘highly unlikely’ and ‘unlikely’ to
harbour clinically significant prostate cancer, respectively, scores of
‘4’ and ‘5’ for glands ‘likely’ and ‘highly likely’ to harbour clinically
significant disease, and a score of ‘3’ for glands in which the
likelihood of the presence of clinically significant cancer was
equivocal. This scoring system was based on the outputs of a
consensus group (Dickinson et al, 2011) that was convened before
the publishing of the PIRADS mpMRI reporting consensus
(Barentsz et al, 2012), although the two systems have subsequently
been found to be similar (Rosenkrantz et al, 2013; Rastinehad et al,
2015). A random selection of 50 cases was re-reported by a second
expert radiologist to allow assessment of interobserver variability.
Reference test. Patients were blinded to the mpMRI results to
minimise non-compliance and selection bias. Men underwent the
reference test (TTPM biopsies) performed according to a set
protocol regardless of the imaging findings and without image
registration regardless of the mpMRI scoring. In summary,
mapping using 5mm sampling was obtained using core needles
inserted via a brachytherapy grid fixed on a stepper. In most
prostates, two biopsies at each grid point were required to sample
the full craniocaudal gland length. All biopsies were reported by
one of two expert uropathologists of420 years of experience each
who were blinded to the mpMRI reports. All negative biopsies were
double-reported for quality control. The cancer core length (CCL)
was reported as the actual amount of cancer seen in each core
without counting the intervening areas of benign glands.
Target condition. As it was inappropriate to use histological
criteria for clinical significance developed for TRUS biopsy, disease
significance was defined by criteria developed and validated for use
with TTPM biopsies (Ahmed et al, 2011). Our primary outcome
was based on the presence of dominant Gleason pattern 4 or
greater (i.e., Gleason X4þ 3) or a CCL involvement of
X6mm in any one location of any Gleason score. We used
definition 2 for secondary outcome analyses (GleasonX3þ 4 and/
or CCLX4mm) as well as the presence of any Gleason score 7 or
more.
Sample size calculation. The sample size calculation was
performed for the primary objective of calculating the negative
predictive value (NPV) of mpMRI, using a precision-based
estimate (Flahault et al, 2005). Targeting an NPV of 90% for
definition one disease, for a binomial 95% confidence interval (CI),
with a confidence width 10%, the number of patients needed with
an absence of clinically significant prostate cancer on the reference
test was 139. Assuming a prevalence of 38% for UCL definition one
disease in the population of interest based on data at our centre,
which we have recently published but available at the time of
designing PICTURE (Valerio et al, 2016), and assuming the
performance characteristics of mpMRI equate to sensitivity and
specificity of B70%, an overall sample size of 316 patients was
needed. As the prevalence of men without clinically significant
disease on the reference test was not precisely known for the
PICTURE study cohort, an interim analysis at 114 recruited men
permitted an adjustment in recruitment to ensure that at least 139
men with a negative reference test were available for analysis.
Statistics. Sensitivity, specificity, PPV and NPV were calculated
for all eligible men with binomial 95% CIs. The index test was
regarded as positive for an mpMRI score of 3 or greater for the
purpose of the primary outcome and on a score of 4 or greater, as
well as other definitions of clinical significance on the TTPM
biopsies. Interobserver agreement was assessed using absolute and
weighted kappa and proportion of agreement and assessed using
area under receiver-operating characteristic (AUROC) curves. The
weighted versions allow for the magnitude of the disagreements to
BRITISH JOURNAL OF CANCER Diagnostic accuracy of multiparametric MRI in men
1160 www.bjcancer.com |DOI:10.1038/bjc.2017.57
be taken into account. The weighting system used resulted in the
weights 0.75, 0.5, 0.25 and 0 for MRI ratings scores that differed by
1, 2, 3 and 4, respectively. STATA version 11.0 software was used
for all analyses with any tests of significance using two-sided
P¼ 0.05 as the threshold for statistical significance.
RESULTS
Baseline characteristics. Three-hundred and thirty men were
enrolled, and following 81 withdrawals, we had 249 completing
both mpMRI and TTPM biopsies (Figure 1, STARD flowchart).
Men eligible for analysis had mean (s.d.) age 62 years (7), median
(IQR) PSA 6.8 ngml 1 (4.8–9.8) and median (IQR) number of
previous biopsies 1 (1–2) and gland size 37ml (26.8–50.0)
(Table 1). One hundred and twenty-one (48.6%) had Gleason 6
disease on TRUS biopsy, while 52 (21.1%) had low volume Gleason
7 disease; 76 (30.5%) had no prior cancer. At TTPM biopsies, a
median (IQR) 49 (40–55) cores were taken. Two hundred and nine
of 249 (84%) in total had cancer on TTPM biopsy. The number of
men free from clinically significant cancer on TTPM biopsies was
146 of 249 (59%) and thus meeting our predefined sample size
assumptions (Table 1).
Primary outcomes. When using mpMRI score ofX3 as a positive
test result, 214 (86%) had a positive prostate mpMRI. For
definition one clinically significant prostate cancer, sensitivity
was 97.1% (92–99), specificity 21.9% (15.5–29.5), NPV 91.4%
(76.9–98.1) and PPV 46.7% (35.2–47.8; Figure 2). Overall accuracy,
as assessed by AUROC, was 0.74 (95% CI 0.68–0.80).
Using mpMRI score X4 as a positive test result, 129 (51.8%)
had a positive mpMRI. For definition of one disease, this conferred
sensitivity of 80.6% (71.6–87.7), specificity of 68.5% (60.3–75.9),
NPV of 83.3% (75.4–89.5) and PPV of 64.3% (55.4–72.6)
(Figure 2). The negative likelihood ratio was 0.13 (0.04–0.42)
and 0.28 (0.19–0.43) for an mpMRI score threshold of 3 and 4,
respectively. Figure 2 illustrates histological outcomes on TTPM
biopsies for each mpMRI score.
Secondary outcomes. We considered two scenarios using mpMRI
to avoid a repeat biopsy. If an mpMRI score of X3 defined a
positive test, this would potentially allow 35 (14%) to avoid a
biopsy with 89 of 214 (41%) clinically insignificant cancers
(definition 1) detected (overdiagnosis) and 3 of 35 (9%) clinically
significant cancers missed (underdiagnosis). If a score ofX4 define
a positive mpMRI, 120 (48%) might avoid a biopsy with 40/129
(31%) clinically insignificant cancers detected (overdiagnosis) and
20 of 120 (17%) clinically significant cancers missed (under-
diagnosis; Table 2). When considering definition 2 clinically
significant cancers, the probability of underdiagnosing this type of
significant cancer increases to B1 in 3 (11 of 35) if men with an
mpMRI reported as 1 or 2 wish to avoid a biopsy. Further, this
would be 1 in 2 (54 of 120) if men with an mpMRI reported as 1, 2
or 3 wish to avoid biopsy (Table 3).
Agreement on the subset of mpMRIs that were double read was
58% (n¼ 29 of 50) with K¼ 0.41 (s.e. 0.08), giving moderate
agreement. Weighted agreement was 87.0% (K¼ 0.52, s.e.¼ 0.10)
indicating good agreement. When comparing mpMRI scores for
each reporter to histology on TTPM biopsies, there were minimal
differences between each reporter in terms of AUROC analyses
(reporter one AUROC 0.76 (0.63–0.90) vs reporter two 0.75
(0.61–0.89)).
Men eligible and recruited for picture, N=330
Men with complete paired data of MRI and TTPM biopsy
N=249
MRI score set at threshold 3 MRI score set at threshold 4
MRI score <4
N=120
MRI score <3
N=35
Significant
N=100 (40.2%)
Significant
N=83 (33.3%)
Significant
N=3 (1.2%)
Significant
N=20 (8.0%)
Insignificant or
benign
N=114 (45.7%)
Insignificant or
benign
N=32 (12.8%)
Insignificant or
benign
N=46 (18.3%)
Insignificant or
benign
N=100 (40.2%)
MRI score 4
N=129
MRI score3
N=214Index test
(mp-MRI)
Reference test
(TTPM-Biopsy)
Evaluable men
Eligible men
Withdrawl, N=91
Gland too large for 5mm sampling (>80ml), N=61
Patient choice, N=9
Medical reasons, N=4
Miscellaneous other, N=7
Figure 1. PICTURE trial flowchart compliant with STARD.
Table 1. Patient demographics
Men enrolled,
n¼330
Men eligible for
analysis following
withdrawals, n¼249
Characteristic
Age (years), mean (s.d.) 63 (7) 62 (7)
PSA at consent (ngml1),
median (IQR)
7.4 (5.3–10.7) 6.8 (4.8–9.8)
Number of previous
biopsies, median (IQR)
1 (1–2) 1 (1–2)
MRI prostate volume (cm3),
median (IQR)
42.0 (28.0–5.0) 37.0 (26.8–50.0)
Histological characteristics
median (IQR)
Total number of
cores
45 (40–55)
Number of cancer
cores
6 (2–11)
MCCL (mm) 4 (2–7)
Gleason score N (%)
Benign 40 (16.1)
3þ 3 66 (26.5)
3þ 4 110 (44.2)
4þ 3 29 (11.7)
X4þ 4 3 (1.2)
3þ 5 1 (0.4)
Abbreviations: IQR¼ interquartile range; MCCL¼MRI, magnetic resonance imaging.
Diagnostic accuracy of multiparametric MRI in men BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.57 1161
In detecting and ruling out definition of two clinically significant
prostate cancer (Gleason X3þ 4 and/or CCL X4mm of any
Gleason score), with an mpMRI score of X3 as a positive
test result, sensitivity was 93.5% (88.6–96.7), specificity 29.6%
(20.0–40.8), NPV 68.6% (50.7–83.1) and PPV 73.4% (66.9–79.2;
Figure 3). Overall accuracy was AUROC 0.76 (0.70–0.82). Table 3
presents scenarios for number biopsied and outcomes if mpMRI
score 3 or 4 were used to designate a positive test.
There were no serious adverse events resulting from mpMRI.
Serious adverse events resulting from TTPM biopsies occurred in 9
(3.6%). Adverse events were assessed in 236 in a median of 38±56
days after biopsy. Haematuria was reported in 220 (93.2%), poor
urine flow in 108 (45.8%) and urinary retention in 56 (23.7%).
Urinary tract infection was diagnosed in 23 (9.8%) and perineal
skin infection in 8 (3.4%). Rectal pain was reported in 59 (25.1%),
perineal pain in 95 (40.3%) and perineal bruising in 136 (57.6%).
De novo erectile dysfunction occurred in 20.8%, with two men
requiring oral medication and the others recovering erectile
function spontaneously after 3–6 weeks.
DISCUSSION
Our PICTURE trial results show that mpMRI in men who require
repeat biopsies is able to accurately rule out clinically significant
prostate cancer as shown by a high sensitivity and NPV. If men
with an mpMRI reported as 1 or 2 wish to avoid a biopsy the
probability of significant cancer is B1 in 10. In our study, this
amounted to two cases with 6mm of Gleason 3þ 3 and a third
case of 2mm of Gleason 4þ 3.
Our study has some limitations. First, the proportion scoring 1 or
2 was small (14%) leading to low specificity. Second, our findings
relate to an expert centre and whether these findings are reproducible
in other non-expert centres requires further evaluation. Third, we
were not able to report to the PIRADS system due to this protocol
being set up before the PIRADS reporting schema. A future study
will need to compare the two reporting systems. Last, our overall
accuracy demonstrated by the AUROC value of 0.74 is somewhat
o0.80 value that is widely accepted to be indicative of an optimal
diagnostic test. This is due to the poor specificity of mpMRI and
further reinforces that when suspicious, mpMRI cannot replace
biopsy due to a high rate of false positives. It also alludes to the
consequent detection of insignificant cancer, especially when a score
threshold of 3 is used to designate a suspicious mpMRI.
Recent systematic reviews assessing the diagnostic accuracy of
mpMRI found sensitivities ranging from 58 to 96%, specificity 23
to 87% and NPV 63 to 98% (de Rooij et al, 2014; Fu¨tterer et al,
2015). The wide ranges reflected differences in mpMRI protocols,
reference standards, study populations, disease prevalence and
mpMRI reporting.
Our study relates to a heterogeneous patient population who had
previous biopsy that was positive or negative. We mitigated any bias
this might cause by our blinding strategy. Further, heterogeneity
improves external validity, although we would advise caution in
applying our results to the biopsy-naive population. The role of
mpMRI in biopsy-naive men is subject to another study called
PROMIS that has been reported recently (Ahmed et al, 2017).
100%
99%
80%
70%
60% TTPM-biopsiesBenign
TTPM-biopsies
Clinically insignificant prostate cancer
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Clinically significant prostate cancer
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Figure 2. Bar chart with associated contingency table demonstrating the histological outcome on TTPM biopsies for each MRI score when using
the primary definition of clinical significant prostate cancer (Gleason X4þ3 and/or maximum CCL X6mm).
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A number of definitions of clinically significant prostate cancer
are available that could have been used to define the target
condition on the reference test (Lord et al, 2011; Valerio et al,
2016). We decided to use histological thresholds developed to
stratify TTPM-biopsy outcomes. Other classification systems such
as the commonly used Epstein criteria are based on using
maximum CCL and the number of positive cores from TRUS
biopsy and cannot be applied to TTPM biopsies.
The prevalence of clinically significant disease was high in
PICTURE, which might be related to the fact that large glands
(480ml) were unable to enter the study as TTPM biopsy would
not be possibly due to bony public arch interference. However,
such a high prevalence has been seen by others when applying
TTPM biopsies to this group of men (Bittner et al, 2015); thus, it is
possible that existing thresholds for clinical significance might need
to be raised (Bratt et al, 2015; Valerio et al, 2016).
Currently, men who require a repeat prostate biopsy face
either a further TRUS biopsy or TTPM biopsies. Some are using
urinary or serum biomarkers to decide who should proceed to a
repeat prostate biopsy. Transrectal ultrasound-guided biopsy can
continue to missclassify with men sometimes requiring a third or
fourth biopsy (Abraham et al, 2015). In addition, TRUS biopsies
carry risk of infection (1–4%) and rising levels of life-threatening
sepsis (0.1%) as they traverse contaminated rectal mucosa with
most men experiencing discomfort and bleeding (Loeb et al, 2013).
On the other hand, TTPM biopsies are highly accurate
(Crawford et al, 2005) and accurately attribute prostate cancer
risk (Valerio et al, 2016). A recent study (Crawford et al, 2013)
comparing TTPM biopsies with whole-mount radical prostatect-
omy specimens it detected in all but one significant prostate cancer
lesion – our protocol used the same 5mm sampling frame in this
study. However, TTPM biopsies require general anaesthesia with a
side-effect profile that is higher than that of TRUS biopsy. The
degree of morbidity, as assessed robustly in PICTURE, is high. The
other disadvantage of TTPM biopsies is the risk of overdetection of
clinically insignificant cancers (Valerio et al, 2016).
Serum and urinary biomarkers also hold promise and offer the
potential of a noninvasive simple test that might allow men to make a
decision whether to avoid a repeat biopsy (Leapman et al, 2016).
However, two biomarkers (prostate health index and PCA3) were
recently deemed less accurate and less cost-effective when compared
with an imaging-based pathway by the UK National Institute of
Table 2. Number of men avoiding biopsy and diagnosis rates
for a target definition for significance on TTPM-biopsy of
definition 1 (Gleason X4+3 and/or maximum cancer core
length X6mm) for each MRI score
mpMRI score threshold for positive
mpMRI SCORE X3 mpMRI SCORE X4
Avoid biopsy 14% (35/249) 48% (120/249)
Biopsy 86% (214/249) 52% (129/249)
Overdiagnosed
insignificant cancer
(of those
undergoing a repeat
biopsy based on
mpMRI)
41% (89/214) 31% (40/129)
Diagnosed
Significant cancer
(of those
undergoing a repeat
biopsy based on
mpMRI)
47% (100/214) 64% (83/129)
Underdiagnosed
significant cancer
(of those not
undergoing a repeat
biopsy based on
mpMRI)
9% (3/35) 8% (20/120)
False positive on
mpMRI (of those
undergoing a repeat
biopsy based on
mpMRI)
12% (25/214) 5% (6/129)
Sensitivity (95%
confidence interval)
97.1% (91.7–99.4%) 80.6% (71.6–87.7%)
Specificity (95%
confidence interval)
21.9% (15.5–29.5%) 68.5% (60.3–75.9%)
NPV (95%
confidence interval)
91.4% (76.9–98.2%) 83.3% (75.4–89.5%)
PPV (95%
confidence interval)
46.7% (39.9–53.7%) 64.3% (55.4–72.6%)
AUROC (95%
confidence interval)
0.60 (0.56–0.63) 0.75 (0.69–0.80)
Abbreviations: AUROC¼ area under receiver-operating characteristic; mpMRI¼multipara-
metric magnetic resonance imaging; NPV¼ negative predictive value; PPV¼positive
predictive value.
Table 3. Number of men avoiding biopsy diagnosis rates for
significance on TTPM-biopsy of definition 2 (Gleason X3+4
and/or maximum cancer core length X4mm) for each MRI
score
mpMRI score threshold for positive
mpMRI score X3 mpMRI score X4
Avoid biopsy 14% (35/249) 48% (120/249)
Biopsy 85% (214/249) 52% (129/249)
Overdiagnosed
insignificant cancer
(of those
undergoing a
repeat biopsy
based on mpMRI)
15% (32/214) 7% (9/129)
Diagnosed
significant cancer
(of those
undergoing a
repeat biopsy
based on mpMRI)
73% (157/214) 88% (114/129)
Underdiagnosed
significant cancer
(of those not
undergoing a
repeat biopsy
based on mpMRI)
31% (11/35) 45% (54/120)
False positive on
mpMRI
26% (57/214) 12% (15/129)
Sensitivity (95%
confidence interval)
93.5% (88.6–96.7%) 67.9% (60.2–74.8%)
Specificity (95%
confidence interval)
29.6% (20.0–40.8%) 81.5% (71.3–89.2%)
NPV (95%
confidence interval)
68.6% (50.7–83.1%) 55.0% (45.7–64.1%)
PPV (95%
confidence interval)
73.4% (66.9–79.2%) 88.4% (81.5–93.3%)
AUROC (95%
confidence interval)
0.62 (0.56–0.67) 0.75 (0.69–0.80)
Abbreviations: AUROC¼ area under receiver-operating characteristic; mpMRI¼multipara-
metric magnetic resonance imaging; NPV¼ negative predictive value; PPV¼positive
predictive value.
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Clinical and Health Excellence (NICE Diagnostics Guideline, 2015).
We acknowledge other fluidic biomarker panels such as the
4-kallikrein panel have demonstrated good performance character-
istics and are undergoing further evaluation.
It is against these options that the role of mpMRI is considered. A
man who is currently advised to undergo a repeat biopsy is faced with
the alternatives of an inaccurate test, which confers a risk of sepsis
(TRUS biopsy) compared with a highly accurate test that requires a
general anaesthetic and confers other forms of morbidity but lower
risk of sepsis (TTPM biopsies). He and his physician, upon looking at
the performance characteristic of mpMRI in an expert centre, may
wish to use this before a decision about repeating the biopsy.
Whether the use of mpMRI before biopsy might be cost-
effective requires further research (Willis et al, 2014; Cerantola
et al, 2016). With an estimated one million prostate biopsies
occurring every year in the United States and B300 000 men
undergoing repeat biopsies, the upfront costs of an mpMRI triage
test need to be offset against the potential benefit ofB30 000 fewer
biopsies and fewer cases of clinically insignificant cancer, which
often get treated unnecessarily. Nonetheless, one should not
underestimate the issues of cost, skills and expertise in reporting
mpMRI and carrying out targeted biopsies (Nassiri et al, 2015).
CONCLUSION
In men currently advised to have a repeat prostate biopsy, prostate
mpMRI could be used to safely avoid a repeat biopsy in 14% while
detecting 97% of clinically significant prostate cancers. However,
men with a non-suspicious mpMRI who avoid an immediate
biopsy should be told of the false-negative rate associated with such
a strategy and undergo clinical follow-up. In addition, the high
prevalence of suspicious mpMRI scans, when a score of 3 is used to
indicate a positive mpMRI leading to biopsy, can also lead to
overdiagnosis of insignificant cancers. Further research is required
to determine whether targeted biopsies in conjunction with
systematic biopsies or alone can achieve the high sensitivity seen
in our PICTURE study.
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Figure 3. Bar chart with associated contingency table demonstrating the histological outcome on TTPM biopsies for each MRI score when
using the secondary definition of clinically significant prostate cancer (Gleason X3þ4 and/or maximum CCL X4mm).
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